Funds
- 2026-05-22 Lilly raises the obesity ceiling again
- 2026-05-22 Datroway moved first in TNBC
- 2026-05-21 Medtronic bought earlier pain intervention
- 2026-05-21 Lilly bought a preclinical delivery wedge
- 2026-05-20 GHO and CBC merged the specialist capital stack
- 2026-05-20 Full-Life raised around the isotope bottleneck
- 2026-05-19 Relay made PI3K vascular anomalies investable
- 2026-05-19 Regeneron paid for a post-ADC option
- 2026-05-15 Tenaya put PKP2 gene therapy into the clinic
- 2026-05-15 Biogen closed the Apellis trade
- 2026-05-14 Regenxbio put DMD back in play
- 2026-05-14 BeOne put BCL-2 into MCL
- 2026-05-13 Isomorphic bought itself a clinical clock
- 2026-05-13 Fosun's AR1001 option, Bizengri's FDA expansion and BioMarin's Amicus integration
- 2026-05-12 BMS-Hengrui megadeal, Rigel's Veppanu handoff and Boehringer-Immunitas antibody bet
- 2026-05-12 BMS paid for Hengrui speed
- 2026-05-11 Novo cell therapy handoff, Vyvgart gMG expansion and Sotyktu EU PsA approval
- 2026-05-11 Inhibrx OX40 data, Daiichi oncology plan and Astellas XLMTM restart
- 2026-05-08 Blackstone's Anagram bet, BeOne pipeline pruning and daraxonrasib NEJM data
- 2026-05-08 ADMA's ASCENIV label, Gyre's Cullgen close and Garda's Assertio tender timing
- 2026-05-07 Roche's PathAI buy, Pathos' DeuterOncology stake and Merck's Terns close
- 2026-05-07 Angelini's Catalyst buy, Entrada's DMD readout and GSK's SiranBio license
- 2026-05-06 Bayer's Perfuse deal, Cytokinetics' nHCM win and CellCentric's Series D
- 2026-05-05 Viridian's TED readout, Vertex's VX-522 stop and Mirum's PSC path
- 2026-05-05 Veppanu approval, Esperion take-private and Sun's Organon deal
- 2026-05-04 UCB's Candid deal, Celcuity's mutant win and Summit's early miss
- 2026-05-01 J&J CAR-T exit, camizestrant ODAC setback and BeOne trispecific option
- 2026-04-30 KalVista takeout, Avalyn IPO and Alector futility
- 2026-04-29 Rusfertide monetization, ATTR exclusivity and imaging margin pressure
- 2026-04-28 SIK3 financing, obesity differentiation and a fast approval for inner-ear gene therapy
- 2026-04-27 In vivo CRISPR de-risking, Lilly's next JAK bet and a shorter medtech coverage clock
- 2026-04-24 Rare oncology exits, European dry powder and a broader SMA gene-therapy lane
- 2026-04-22 In vivo CAR-T pricing, ocular gene therapy capital and a cleaner immunology setup
- 2026-04-21 Lupus filing, modified DNA and cath-lab software economics
- 2026-04-20 Forma payoff, felzartamab control and the IPO window test
- 2026-04-18 ADC platform buying, radiopharma partnering and a $300M autoimmune NewCo